RxDoctor Payments DataLook up a doctor →

Elizabeth Thiele, MD

Neurology with Special Qualifications in Child Neurology · Boston, MANPI 1982670535

Payments from drug & device makers

$1,408,558in general payments, 2019–2025

Across 294 payments — averaging $4791.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GW Research Limited$703K
  • Jazz Pharmaceuticals Inc.$188K
  • UCB, Inc.$126K
  • UCB SA$97K
  • Greenwich Biosciences, Inc.$84K
  • Zogenix Inc.$79K
  • plus $132K from 20 others

What the payments were for

  • Consulting fees$219,59179%
  • Speaking & faculty fees$29,91211%
  • Travel & lodging$23,9979%
  • Food & beverage$4,3232%
  • Education$260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,408,558 in reported general payments places this provider in the 95th percentile of 101 neurology with special qualifications in child neurology providers in Massachusetts.

See all neurology with special qualifications in child neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$15,399
Medicare patients
61
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)229$1,373,739
Vigabatrin29$321,366
FinteplaFenfluramine Hcl14$273,736
XcopriCenobamate194$255,282
Lamictal XrLamotrigine83$243,894
OnfiClobazam44$159,324
HyftorSirolimus36$144,166
NayzilamMidazolam65$130,367
KeppraLevetiracetam71$127,234
TopamaxTopiramate13$80,925
AptiomEslicarbazepine Acetate34$75,023
VimpatLacosamide41$44,821
Clobazam279$36,178
NeurontinGabapentin13$34,947
Depakote SprinkleDivalproex Sodium27$32,452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Fintepla, Nayzilam, Vimpat$126,430$448,924120 claims
SK Life Science, Inc.Xcopri$14,005$255,282194 claims
Lundbeck LLCOnfi$3,919$159,32444 claims
Nobelpharma America, LLCHyftor$1,290$144,16636 claims
UCB SAKeppra$96,823$127,23471 claims
Sunovion Pharmaceuticals Inc.Aptiom$22$75,02334 claims
Neurelis, Inc.Valtoco$10,738$22,89113 claims
Eisai Inc.Fycompa$1,680$18,79915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 101 neurology with special qualifications in child neurology providers in Massachusetts.

Other neurology with special qualifications in child neurology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →